GlassScriptPhysician profile
John P Bercier
NPI 1588168199
$5,093.47
in general payments reported to CMS, 2019-2025
19 companies · $4,237 in 2025
The $4,237 reported for 2025 was more than what 92% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.65 · 2023: $56.13 · 2024: $785 · 2025: $4,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,072 · Education: $1,500 · Travel and Lodging: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,071.94 |
| Education | $1,500.00 |
| Travel and Lodging | $505.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,083.18 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $736.38 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $376.70 | 2023-2025 | Dupixent |
| Genzyme Corporation | $314.71 | 2024-2025 | |
| Viatris Specialty LLC | $270.77 | 2025 | Yupelri |
| Grifols USA, LLC | $265.43 | 2024-2025 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $218.76 | 2025 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $188.06 | 2024-2025 | Winrevair, Capvaxive, Lagevrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.93 | 2024-2025 | Jascayd, Ofev |
| Insmed, INC. | $98.03 | 2024-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $83.81 | 2024-2025 | Opsynvi, Uptravi, Opsumit |
| Amgen INC. | $72.37 | 2025 | Tezspire |
| Baxter Healthcare | $68.25 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $41.45 | 2025 | Ohtuvayre |
| Csl Behring | $26.68 | 2024 | Hizentra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $24.62 | 2024 | Yupelri |
| Pulmonx Corporation | $22.07 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| La Jolla Pharmaceutical Company | $19.47 | 2025 | Giapreza |
| Electromed, INC. | $16.80 | 2024 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bercier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.